Searched for
LAL PATHLABS
Smallcaps & midcaps rally! Firstsource Solutions, Nuvama, Godfrey Phillips, other stocks jump up to 16%Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...- Smallcaps continue to draw domestic flows, stock selection key: Sandip SabharwalIndian equity markets show resilience post-election results. Market expert Sandip Sabharwal notes that governance and policy continuity are...
- Dr. Lal Pathlabs among 5 stocks showing bullish RSI upswingFive stocks from the Nifty500 universe were flagged in the RSI Trending Up scan on May 4 after gaining over 4%. The indicator turned positi...
- Positive Breakout: These 14 stocks cross above their 200 DMAsAs long as the stock is priced above the 200-day SMA on the daily timeframe, it is generally considered to be in an overall uptrend.
- Forget the noise: These 54 smallcap stocks attracted FII buying in March quarterForeign institutional investors are strategically buying into beaten-down smallcap stocks in India, increasing stakes in 54 companies despi...
- Dr. Lal PathLabs shares turn ex-bonus tomorrow for 1:1 issue, last day to buy for eligibilityAs per the corporate filings, the company will issue one fully paid-up bonus equity share of face value Rs 10 for every one existing fully ...
- Buy Dr. Lal Pathlabs, target price Rs 3181: BNP Paribas SecuritiesDr. Lal Pathlabs Ltd., incorporated in the year 1995, is a Mid Cap company (having a market cap of Rs 19103.91 Crore) operating in Hospital...
- Dr Lal PathLabs Q3 Results: Net profit drops 8% to Rs 54 croreDr Lal PathLabs said its emphasis is on improving the market penetration through franchisee model, and leveraging the digital infrastructur...
- Dr Lal PathLabs to use drones for transporting blood samplesThe use of drones would expand Dr Lal PathLabs services of high-quality and advanced diagnostics to underserved and inaccessible locations,...
- Dr Lal PathLabs Q2 results: Net profit up 11% at Rs 96 croreOperating revenue of the company increased by 15.4 per cent in Q2 FY22 to Rs 498.4 crore as compared with Rs 431.9 crore in Q2 FY21, Dr Lal...
- Dr Lal PathLabs Q4 results: Net profit jumps over 2.5 times to Rs 85 crIts consolidated revenue from operations stood at Rs 431 crore for the quarter under consideration. It was Rs 301.7 crore for the same peri...
- Dr Lal PathLabs Q2 results: Net profit up 7.5% to Rs 87 crRevenue from operations stood at Rs 431.9 crore for the quarter under consideration. It was Rs 365.6 crore for the same period a year ago, ...
- Dr Lal PathLabs Q1 results: Net profit declines 52% to Rs 28.4 croreThe company had posted a net profit of Rs 59.1 crore for the corresponding period of the previous fiscal, Dr Lal PathLabs said in a filing ...
- Dr Lal PathLabs Q4 results: Net profit declines 31% to Rs 32.6 croreThe company had posted a net profit of Rs 47.4 crore for the corresponding period of previous fiscal.
- Dr Lal PathLabs to acquire 70 pc stake in Amins Pathology Referral LaboratoryThe acquisition will further strengthen the company's network in Gujarat and adjoining areas
- CLSA maintains 'buy' on Dr Lal PathLabsDr Lal PathLabs' volume growth in the past two quarters has been encouraging.
- Nomura upgrades Dr Lal PathLabs to 'buy' from 'neutral'The brokerage said growth in recent times in Dr Lal PathLabs has been hit by demonetisation but it remains constructive on long term growth...
- Dr Lal PathLabs Q3 profit more than doubles to Rs 61 croreDr Lal PathLabs today reported over two-fold jump in consolidated net profit at Rs 60.82 crore for the third quarter ended December 31, 201...
- TA Associates buys minority stake in Lal PathLabsTA Associates made a minority investment in Dr Lal PathLabs by purchasing half of Sequoia Capital’s stake in the company for an undisclosed...
- Sequoia to sell around 15% in PathLabsSequoia Capital has put a part of its 30% stake in one of the country’s largest diagnostics and pathology services chain, Dr Lal PathLabs, ...
Load More
